The purpose of this study was to determine the effects of PAF treatment of rabbit spermatozoa on in vitro fertilization and subsequent blastocyst formation. Rabbit spermatozoa were exposed to PAF (10-7 M ), lyso-PAF (10-7 M ), or HIS (385 mOsm/kg) for 15 min prior to insemination of ovulated oocytes. Fertilized oocytes were cultured to the hatched blastocyst stage.

Background: Cervical cancer is the most common gynecological malignant disorder worldwide. Activated platelets play a key role in cancer development and progression. Mean platelet volume (MPV) is an early indicator of platelet activation. The aim of the present study was to evaluate MPV levels in patients with cervical cancer. Materials and methods: A total of 181 patients with cervical cancer and 181 controls between January 2015 and June 2015 were included in the study. Patient characteristics and hematologic test data at initial diagnosis were collected and odds ratios (ORs) and 95% confidence intervals (CIs) for risk of cervical cancer were calculated using multivariate logistic regression analyses across MPV quartiles. Results: MPV levels were decreased in patients with cervical cancer compared with control subjects. A significant correlation between MPV and FIGO stage was found. Moreover, after adjusting for other risk factors, the ORs (95%CIs) for cervical cancer according to MPV quartiles were 4.450 (1.975-10.026), 2.505 (1.206-5.202), 0.573 (0.261-1.259), and 1.000, respectively. Conclusions: MPV was found to be independently associated with the presence of cervical cancer. Our results suggest that MPV could be potential diagnostic screening tool.

Thesis (MSD) --Boston University, Henry M. Goldman School of Dental Medicine, 2009 (Department of Periodontology and Oral Biology). / Includes bibliographic references: leaves 52-59. / Platelet-rich plasma (PRP) is a concentrated gel of platelets that contains several growth factors. Growth factors have been recognized as the part of PRP that play role in regeneration of the bone. It is not clear how these growth factors in PRP affect the bone regeneration. Resolvin El (RvEl; 5S,12R,18R-trihydroxyeicosapentaenoic acid) is an pro-resolving lipid mediator derived from omega-3 fatty acid eicosapentaenoic acid and shown to have potent effects on the resolution of inflammation. The purpose of this study was to analyze the action of PRP and RVEl on the proliferation and behavior of osteoblasts and osteoclasts in vitro. PRP was prepared from 14 healthy donors. Osteoblast cultures were from a cell line (Saos2) of osteosarcoma cells. Osteoclasts were differentiated from primary human peripheral blood monocytes. Osteoclastic morphology was studied and activity was analyzed via resorption on dentin discs using SEM. PRP and RVE 1 were added at different doses and time-points. Osteoblast function was analyzed by osteocalcin expression and release. Osteoclast activity was assessed by resorption and cathepsin K expression. PRP and RvEl comparably increased the osteoblastic activity and suppressed the osteoclast differentiation and function. These results suggest that multiple tools are available to reverse the inflammation and restore the lost bone architecture as a result of periodontal disease.

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第18512号 / 医博第3932号 / 新制||医||1006(附属図書館) / 31398 / 京都大学大学院医学研究科医学専攻 / (主査)教授 髙折 晃史, 教授 前川 平, 教授 小川 誠司 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第19565号 / 医博第4072号 / 新制||医||1013(附属図書館) / 32601 / 京都大学大学院医学研究科医学専攻 / (主査)教授 江藤 浩之, 教授 前川 平, 教授 髙折 晃史 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第21454号 / 医博第4421号 / 新制||医||1033(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 渡邊 直樹, 教授 髙折 晃史, 教授 山下 潤 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

Trombocyttransfusion är en viktig behandlingsmetod för att antingen förebygga eller förhindra blödning. Trombocyter för transfusion (trombocytkoncentrat) framställs med två metoder: antingen genom aferesteknik eller genom att separera helblodet i erytrocytenhet, plasma, leukocytenhet och interim platelet unit (IPU). Sedan placeras IPU-enheter på en agitationsmetod. Efter det framställs trombocytkoncentrat genom att poola 4–6 IPU  tillsammans med platelet additive solution (PAS). Syftet med denna studie var att undersöka en ny agitationsmetod för framställning av trombocytkoncentrat, Trombomixer 307, och jämföra den med nuvarande agitationsmetoden, trombocytvagga. Dessutom att undersöka om införandet av Trombomixer 307 kan minska antal IPU-enheter som har  trombocytaggregat. Studien utfördes genom att placerade 100 IPU-enheter på trombocytvagga och 100 placerades på Trombomixer 307. Dessutom framställdes totalt 56 trombocytkoncentrat (28 från Trombomixer 307 och 28 från trombocytvagga) som sedan undersöktes genom kvalitetskontroll av platelet yield index-summa (PYI-värde), volymen, leukocytpartikalkoncentration (LPK) och trombocytpartikalkoncentration (TPK). Resultaten visade att 31 av de 100 IPU-enheterna på Trombomixer 307 hade trombocytaggregat, medan 47 av de 100 IPU-enheter från trombocytvagga hade trombocytaggregat. IPU-enheter på Trombomixer hade en signifikant färre antal IPU-enheter som hade trombocytaggregat jämfört med IPU-enheter från trombocytvagga (p = 0,029). Dessutom visade resultateten att trombocytkoncentrat från Trombomixer hade lägre LPK- och TPK-värde jämfört med trombocytkoncentrat från trombocytvagga. Trombocytkoncentrat från trombocytvagga visade bättre korrelation mellan PYI-summa och TPK-värde. Slutsatsen är att Trombomixer 307 uppfyller krav som en agitationsmetod för framställning av trombocytkoncentrat och att Trombomixer 307 minskar andelen  IPU-enheter som har bildat trombocytaggregat. Dock leder trombocytvagga till bättre kvalitet av trombocytkoncentrat. / Platelet transfusion is a treatment to prevent or stop bleeding. Platelets for transfusion (platelet-concentrate) are produced by separating the blood into erythrocyte-unit, plasma, leukocyte-unit, and interim platelet-unit (IPU). The IPUs are then placed on an agitation method. Platelet-concentrate is prepared by pooling 4–6 IPUs with platelet additive solution (PAS). The purpose of this study was to examine Trombomixer 307 as new agitation method for producing platelet-concentrate, and compare it with the current agitation method, the platelet-rocker. It is also investigated whether the implantation of the Trombomixer 307 can reduce the number of aggregated IPUs. The study was performed by placing 100 IPUs on the platelet-rocker and 100 IPUs on the Trombomixer 307. Additionally, 56 platelet-concentrates were prepared (28 from the Trombomixer 307 and 28 from the platelet-rocker), which then examined through quality control of the platelet yield index sum (PYI value), volume, leukocyte particle concentration (LPK) and platelet particle concentration (TPK). The results showed that 31 out of the 100 IPUs from Trombomixer and 47 of the 100 IPUs from the platelet-rocker were aggregated. IPUs from the Trombomixer had a significantly lower number of aggreged IPUs compared to IPUs from the platelet rocker (p = 0.029). The results also showed that platelet-concentrate from Trombomixer had lower LPK and TPK, while Platelet-concentrate from platelet-rocker showed better correlation between PYI sum and TPK. In conclusion, Trombomixer 307 fulfills requirements as an agitation method to produce platelet-concentrates and reduces the percentage of aggregated IPUs. However, platelet-rocker leads to better quality of platelet-concentrate.

Animal models have been recognized for the valuable roles they serve in both animal and human medicine. Dogs share many of the same naturally occurring tumors as humans including osteosarcoma, lymphoma, and mammary tumors. In addition, dogs share the same environment as humans, have a shorter lifespan, and often have a quicker progression of disease, making them an attractive model of human disease. Platelets are small anucleate cell fragments that have essential roles in hemostasis, angiogenesis, and wound healing, and, more recently recognized, roles in development, survival, growth, and metastasis of various cancers. Their roles in angiogenesis has proven to be both directly and indirectly linked to tumor growth due to the angiogenic roles they play in the development of tumor blood supply. Being able to study the interactions and mechanisms between platelets and tumor cells at the protein level, through proteomics, would allow great insight into the effects of platelets on tumor cell behavior as well as potential biomarker identification and therapeutic development. The objective of this research is to integrate the roles of canine platelet proteins into a better understanding of the effects and interactions that platelets have with different tumor cells while utilizing the canine model of neoplasms commonly affecting their human counterparts. The first study in this research describes an efficient technique developed for the purification of canine platelets from clinically relevant volumes of whole blood with high platelet recovery and minimal contamination from other blood cells. The second study describes a non-electrophoretic detergent fractionation technique used for the digestion of canine platelet samples for proteomic analysis as well as description of the proteomic findings for the normal canine platelet. Lastly, the third study describes the proteomic analysis of proteins differentially expressed by canine osteosarcoma and mammary tumor cells following incubation with canine platelet lysate in vitro. Overall, findings of this research support the canine model of human cancers and provide comprehensive information regarding canine platelet proteomics as well as novel efficient techniques that aid the future of canine platelet-tumor cell interaction research

This document only includes an excerpt of the corresponding thesis or dissertation. To request a digital scan of the full text, please contact the Ruth Lilly Medical Library's Interlibrary Loan Department (rlmlill@iu.edu).

This study monitored the storage lesion of 15 units of canine platelet concentrates harvested by differential centrifugation. Canine platelet concentrates were stored at 20-24°C in a platelet rotator for a total of 9 days; the storage lesion of three second generation platelet storage containers was compared. The battery of in vitro tests used to monitor the storage lesion were selected from previous studies performed with human platelet concentrates separated by differential centrifugation. Based on these tests, canine platelet concentrates exhibited a storage lesion similar to human platelet concentrates. Metabolic analytes demonstrated decreasing pH, carbon dioxide, bicarbonate and glucose concentrations concurrent with increasing oxygen and lactate dehydrogenase activity over the 9-day period. Platelet structural changes were monitored by mean platelet volume, which began to increase on Day-5. Platelet function appeared to be compromised, as indicated by aggregation studies using collagen and adenosine diphosphate as agonists. Product sterility was maintained. There was no consensus of data supporting superior performance of one platelet storage container. This study indicates that canine platelet concentrates may be harvested by differential centrifugation of whole blood. In vitro studies utilizing three second-generation platelet storage bags support a previous study and concurs that canine platelet concentrates stored at 20-24°C using continuous agitation are viable for at least 5 days. / Master of Science